Ahmed Sawas

2.1k total citations
68 papers, 1.0k citations indexed

About

Ahmed Sawas is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Ahmed Sawas has authored 68 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pathology and Forensic Medicine, 30 papers in Oncology and 17 papers in Genetics. Recurrent topics in Ahmed Sawas's work include Lymphoma Diagnosis and Treatment (38 papers), Chronic Lymphocytic Leukemia Research (16 papers) and CAR-T cell therapy research (14 papers). Ahmed Sawas is often cited by papers focused on Lymphoma Diagnosis and Treatment (38 papers), Chronic Lymphocytic Leukemia Research (16 papers) and CAR-T cell therapy research (14 papers). Ahmed Sawas collaborates with scholars based in United States, Canada and Italy. Ahmed Sawas's co-authors include Owen A. O’Connor, Dejan Radeski, Jennifer E. Amengual, Changchun Deng, Ranjana H. Advani, Ann S. LaCasce, Stephen M. Ansell, Jennifer Kimberly Lue, Julie M. Vose and Neil C. Josephson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ahmed Sawas

65 papers receiving 1.0k citations

Peers

Ahmed Sawas
Sha Zhao China
Ilseung Choi Japan
Junichi Kiyasu Japan
Rosita L. ten Berge Netherlands
Lekidelu Taddesse-Heath United States
Kôji Nanba Japan
Martina Prochazkova‐Carlotti France
S. Poppema Netherlands
Keisuke Kawamoto Japan
Martin Barrett United Kingdom
Sha Zhao China
Ahmed Sawas
Citations per year, relative to Ahmed Sawas Ahmed Sawas (= 1×) peers Sha Zhao

Countries citing papers authored by Ahmed Sawas

Since Specialization
Citations

This map shows the geographic impact of Ahmed Sawas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmed Sawas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmed Sawas more than expected).

Fields of papers citing papers by Ahmed Sawas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmed Sawas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmed Sawas. The network helps show where Ahmed Sawas may publish in the future.

Co-authorship network of co-authors of Ahmed Sawas

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmed Sawas. A scholar is included among the top collaborators of Ahmed Sawas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmed Sawas. Ahmed Sawas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tolu, Seda S., Caitlin Gribbin, Zhengming Chen, et al.. (2025). Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents. Leukemia & lymphoma. 66(13). 2437–2447.
2.
Kim, Won Seog, Jake Shortt, Pier Luigi Zinzani, et al.. (2024). A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas. Clinical Cancer Research. 31(1). 65–73. 7 indexed citations
3.
Polito, Letizia, Navdeep Pal, Ahmed Sawas, et al.. (2024). Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting. Frontiers in Pharmacology. 15. 1223858–1223858. 4 indexed citations
4.
Xu, Tao, Ahmed Sawas, Wan‐Jen Hong, et al.. (2023). RWD-derived response in multiple myeloma. PLoS ONE. 18(5). e0285125–e0285125. 1 indexed citations
5.
6.
Sawas, Ahmed, Helen Ma, Andrei R. Shustov, et al.. (2019). Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL). Blood. 134(Supplement_1). 4050–4050. 5 indexed citations
7.
Phillips, Adrienne A., Paul Fields, Olivier Hermine, et al.. (2019). Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Repositorio Académico USMP. 5 indexed citations
8.
Khan, Shaheer & Ahmed Sawas. (2019). Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL. Frontiers in Oncology. 9. 645–645. 12 indexed citations
9.
Phillips, Adrienne A., Paul Fields, Olivier Hermine, et al.. (2018). Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 104(5). 993–1003. 48 indexed citations
10.
Sawas, Ahmed, Charles M. Farber, Marshall T. Schreeder, et al.. (2017). A phase 1/2 trial of ublituximab, a novel anti‐ CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. British Journal of Haematology. 177(2). 243–253. 61 indexed citations
11.
Amengual, Jennifer E., Jennifer Kimberly Lue, Ahmed Sawas, et al.. (2017). A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 131(4). 397–407. 91 indexed citations
12.
Falchi, Lorenzo, Jennifer Kimberly Lue, Jennifer E. Amengual, et al.. (2017). A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL). Blood. 130. 1515–1515. 10 indexed citations
13.
14.
Amengual, Jennifer E., Ahmed Sawas, Changchun Deng, et al.. (2016). The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood. 128(22). 1824–1824. 3 indexed citations
15.
LaCasce, Ann S., Gregory Bociek, Ahmed Sawas, et al.. (2015). Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 126(23). 3982–3982. 43 indexed citations
16.
Amengual, Jennifer E., et al.. (2015). Will new drugs change the standard of care for patients with mantle cell lymphoma?. Expert Review of Anticancer Therapy. 16(2). 199–210. 1 indexed citations
17.
LaCasce, Ann S., R. Gregory Bociek, Jeffrey Matous, et al.. (2014). Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy. Blood. 124(21). 293–293. 20 indexed citations
18.
O’Connor, Owen A., Changchun Deng, Jennifer E. Amengual, et al.. (2014). A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.. Journal of Clinical Oncology. 32(15_suppl). 8524–8524. 8 indexed citations
19.
Burack, Joshua H., Emad Kandil, Ahmed Sawas, et al.. (2007). Triage and Outcome of Patients with Mediastinal Penetrating Trauma. The Annals of Thoracic Surgery. 83(2). 377–382. 42 indexed citations
20.
Chughtai, Bilal, et al.. (2005). A neglected gland: a review of Cowper's gland. International Journal of Andrology. 28(2). 74–77. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sha Zhao Breakdown of academic impact, for papers by Ilseung Choi Breakdown of academic impact, for papers by Junichi Kiyasu Breakdown of academic impact, for papers by Rosita L. ten Berge Breakdown of academic impact, for papers by Lekidelu Taddesse-Heath Breakdown of academic impact, for papers by Kôji Nanba Breakdown of academic impact, for papers by Martina Prochazkova‐Carlotti Breakdown of academic impact, for papers by S. Poppema Breakdown of academic impact, for papers by Keisuke Kawamoto Breakdown of academic impact, for papers by Martin Barrett
Rankless by CCL
2026